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Abstract: Following infection, HIV establishes reservoirs within tissues that are inaccessible to 
optimal levels of antiviral drugs or within cells where HIV lies latent, thus escaping the action 
of anti-HIV drugs. Macrophages are a persistent reservoir for HIV and may contribute to the 
rebound viremia observed after antiretroviral treatment is stopped. In this study, we further 
investigate the potential of poly(lactic-co-glycolic) acid (PLGA)-based nanocarriers as a new 
strategy to enhance penetration of therapeutic molecules into macrophages. We have prepared 
stable PLGA nanoparticles (NPs) and evaluated their capacity to transport an active molecule 
into the human monocyte/macrophage cell line THP-1 using bovine serum albumin (BSA) as a 
proof-of-concept compound. Intracellular localization of fluorescent BSA molecules encapsu-
lated into PLGA NPs was monitored in live cells using confocal microscopy, and cellular uptake 
was quantified by flow cytometry. In vitro and in vivo toxicological studies were performed to 
further determine the safety profile of PLGA NPs including inflammatory effects. The size of the 
PLGA NPs carrying BSA (PLGA-BSA) in culture medium containing 10% serum was ~126 nm 
in diameter, and they were negatively charged at their surface (zeta potential =−5.6 mV). Our 
confocal microscopy studies and flow cytometry data showed that these PLGA-BSA NPs are 
rapidly and efficiently taken up by THP-1 monocyte-derived macrophages (MDMs) at low doses. 
We found that PLGA-BSA NPs increased cellular uptake and internalization of the protein 
in vitro. PLGA NPs were not cytotoxic for THP-1 MDM cells, did not modulate neutrophil 
apoptosis in vitro, and did not show inflammatory effect in vivo in the murine air pouch model 
of acute inflammation. In contrast to BSA alone, BSA encapsulated into PLGA NPs increased 
leukocyte infiltration in vivo, suggesting the in vivo enhanced delivery and protection of the 
protein by the polymer nanocarrier. We demonstrated that PLGA-based nanopolymer carriers are 
good candidates to efficiently and safely enhance the transport of active molecules into human 
MDMs. In addition, we further investigated their inflammatory profile and showed that PLGA 
NPs have low inflammatory effects in vitro and in vivo. Thus, PLGA nanocarriers are promis-
ing as a drug delivery strategy in macrophages for prevention and eradication of intracellular 
pathogens such as HIV and Mycobacterium tuberculosis.
Keywords: PLGA nanoparticles, BSA delivery, inflammatory profile, neutrophil apoptosis, 
murine air pouch, HIV reservoir
Introduction
HIV/AIDS remains one of the world’s most significant public health challenges, par-
ticularly in low- and middle-income countries (UNAIDS, 2014). The introduction of 
highly active antiretroviral therapy in 1996 has, over time, been a great medical success 
in terms of increasing survival and improving the quality of life of the HIV-infected 
patient population. However, this therapy is not able to eradicate HIV from infected 
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individuals.1–3 During the very early stages of infection, HIV 
establishes reservoirs within tissues that are inaccessible to 
optimal levels of antiviral drugs or within cells where HIV 
lies latent, thus escaping the action of anti-HIV drugs.4–6 
Reservoir sites protect the virus from biological elimina-
tion pathways, immune response, and antiretroviral drugs; 
allow viral dissemination throughout the body; serve as a 
major source of viral rebound upon treatment failure, and 
contribute to the development of drug resistance.7–10 Resting 
CD4+ cells are known to be the main cellular reservoir for the 
latent HIV-1 infection due to their ability to persist for a long 
span, but other cellular reservoirs have been described to play 
an important role in HIV persistence including monocytes 
and macrophages, which are the most important reservoirs 
outside the bloodstream.7,8,11–16 Monocytes/macrophages are 
relatively long-lived cells since HIV has very low cytopathic 
effects on them, making them a persistent reservoir of HIV 
regardless of the presence of highly active antiretroviral 
therapy.8,15–17 Monocytes and macrophages express efflux 
transporters, which contribute to maintain subtherapeutic 
concentrations of antiretroviral medications in these cells 
and may explain why macrophages are sanctuaries for HIV.18 
Therefore, eliminating or preventing viral infection in mac-
rophages is a key element to achieve viral eradication, and 
new strategies to enhance penetration of antiviral therapeutics 
in macrophages are thus urgently needed.
One promising approach to target HIV in reservoir sites 
is the use of nanomedicine.19–24 The potential advantages of 
using nanoformulations over conventional HIV therapies 
include the capacity to incorporate, encapsulate, or conjugate 
a variety of drugs to offer tunable and site-specific targeting 
and drug release.25 In addition, the use of nanosystems to 
deliver a therapeutic molecule can overcome biological barri-
ers; improve drug stability, solubility, and bioavailability; and 
reduce side effects.26–28 A wide range of nanomaterials have 
been used and evaluated for their efficiency to deliver HIV-1 
therapeutics.25,29 Particular interest has been focused on poly-
meric particles prepared from polyesters such as poly(lactic-
co-glycolic) acid (PLGA), poly(lactide), and polyglycolide 
due to their biocompatibility and biodegradability and their 
approval by the US Food and Drug Administration for use 
in drug delivery and biomaterial applications.30–32 Various 
polymeric nanomedicines have been developed for the 
delivery of antiretroviral drugs in HIV reservoir sites, giving 
some hope for viral eradication.20,24 However, despite major 
breakthroughs in the development of nanopolymeric particles 
for vaccine and drug delivery into macrophages, there are 
still many limitations to overcome before their use in clinical 
applications.33,34 Although PLGA co-polymer has been used in 
several studies as micro/nanoparticles (NPs) delivery systems 
with a certain degree of success20,30,32,35–37 including delivery 
of antimicrobial drugs into monocytes/macrophages,29,38–42 
their safety for therapeutic application is still unknown. 
Indeed, few studies have focused on the inflammatory profile 
of PLGA nanopolymeric carriers and, to our knowledge, no 
study has yet investigated the effect of PLGA-based NPs 
on polymorphonuclear neutrophil (PMN) apoptosis and 
recruitment. PMNs are key players in innate immunity and 
inflammation, thus determining whether PLGA-based NPs 
interfere with neutrophil function is crucial for the further 
development of PLGA-based nanomedicines.
Therefore, the aim of this research was to further 
evaluate the potential of PLGA-based NPs in delivery 
strategies to target HIV in the macrophage cellular reservoir 
and to further investigate their inflammatory properties 
by determining their effect on PMNs. We designed and 
characterized a PLGA-based nanocarrier for the delivery 
of therapeutic agents in human monocyte-derived mac-
rophages (MDMs). Bovine serum albumin (BSA) was used 
as the model protein/drug to investigate more specifically 
the potential of PLGA nanomaterials to serve as nanocar-
riers for antimicrobial or antigenic proteins for future 
microbicide and vaccine development, respectively. The 
PLGA NPs were prepared by the double emulsion method 
and characterized in terms of various physicochemical 
properties, cellular uptake and internalization, cytotoxicity, 
and inflammatory properties including interference with 
neutrophil apoptosis and recruitment in a pro-inflammation 
animal model.
Materials and methods
Materials
Biodegradable PLGA 50:50 polymer of 7,000–17,000 daltons 
average molecular weight (MW), BSA, and fluorescein iso-
thiocyanate (FITC)-labeled BSA were all purchased from 
Sigma-Aldrich Co. (St Louis, MO, USA). Polyvinyl alcohol 
(PVA) of 6,000 daltons average MW was purchased from 
Polysciences, Inc. (Warrington, PA, USA). Titanium dioxide 
(TiO
2
) was obtained from Vive Nano (Toronto, ON, Canada). 
Bradford Protein Assay kit was purchased from Bio-Rad Labo-
ratories Inc. (Hercules, CA, USA). Roswell Park Memorial 
Institute (RPMI) 1640 cell culture medium, phosphate buffered 
saline (PBS), and Hank’s Balanced Salt Solution (HBSS) were 
all purchased from Thermo Fisher Scientific (Waltham, MA, 
USA). CellTiter-Blue® Cell Viability Assay was obtained 
from Promega Corporation (Fitchburg, WI, USA). Milli-Q 
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and deionized water were produced by a Millipore water 
purification system (EMD Millipore, Billerica, MA, USA).
Preparation of nanoparticles
Antigenic protein-loaded biodegradable NPs were prepared 
by a double-emulsion (water/oil/water) method with subse-
quent solvent evaporation.41 BSA was used as a model protein. 
Briefly, BSA or FITC-BSA (8 mg) was first dissolved in water 
(1 mL) and then added to a solution of 150 mg of PLGA 50:50 
(7,000–17,000 dalton MW) dissolved in chloroform (6 mL). 
The mixture was sonicated for 45 seconds using a Branson 
Sonifier 250 fitted with a Branson tapered microtip (3 mm) 
(Branson Sonifier® Cell Disrupters; Branson Electronics, 
VWR, Missisauga, ON, Canada) to form the first water-in-
oil emulsion. The power of the tip sonicator was set at 60% 
duty cycle and was operated at maximum power (200 W). 
This water-in-oil emulsion was added to a solution of 2.5% 
(v/v) PVA (6,000 dalton MW) dissolved in water (50 mL) 
to form a water-in-oil-in-water double-emulsion. Sonication 
of the double-emulsion was performed at room temperature 
for 5 minutes to reduce droplet size to the nanosize range 
followed by evaporation of the organic solvent chloroform 
under vacuum to form PLGA-BSA and PLGA-FITC-BSA 
NPs. Again the power was 200 W with a 60% duty cycle. The 
PLGA NPs were then washed several times by centrifuga-
tion (14, 000 rpm, 4°C, 45 minutes) to remove the unbound 
protein and adsorbed PVA from the surface of the NPs and 
resuspended in a d-glucose (dextrose) solution. The NPs were 
then flash frozen with liquid nitrogen, freeze dried, and stored 
at −20°C until their use. Unloaded PLGA NPs were prepared 
using the same method except BSA was not added to the water 
during formation of the first water-in-oil emulsion. For the 
in vitro and in vivo studies, NPs were reconstituted in sterile 
water, and the suspensions were filtered through a sterile 
membrane with a pore size of 0.45 µm (EMD Millipore) and 
then kept at 4°C until their use. Freshly prepared NP batches 
were used unless otherwise noted.
Physicochemical characterization
The morphology of the NPs was analyzed using a Philips CM20 
FEG transmission electron microscope operating at 200 kV. 
Images were obtained by drop-coating the PLGA NPs sus-
pension onto 400 mesh copper grids with a precoated layer of 
holey carbon. Particle size and size distribution were measured 
by dynamic light scattering (DLS) using a Malvern Zetasizer 
Nano-ZS (Malvern Instruments, Malvern, UK). The width of 
the DLS hydrodynamic diameter distributions is indicated by 
the polydispersity index. Zeta potential was determined using 
the same instrument. NP suspensions were vortexed before 
analysis, and each sample was measured in triplicates.
Encapsulation efficiency
The amount of BSA and FITC-BSA contained in the NPs 
was spectrophotometrically determined directly after the 
extraction of the protein from the NPs. Briefly, the PLGA-
BSA and PLGA-FITC-BSA NPs were treated with a solution 
of 2 M NaOH during 2 hours to allow degradation of the 
polymeric matrix and release of encapsulated BSA or FITC-
BSA, respectively, from the NPs. The suspension was then 
centrifuged at 15,000 rpm for 15 minutes. Supernatant was 
collected, and the amount of protein released from the NPs 
was determined using a Bradford Protein Assay kit according 
to the manufacturer’s instructions. Absorbance was measured 
at 595 nm by a Synergy Mx multimode microplate reader 
(Biotek, Winooski, VT, USA) with the Gen5 Data Analysis 
Software. The amount of unbound BSA or FITC-BSA found 
in the supernatant was also measured after each of the three 
washes during the synthesis of the PLGA-BSA and PLGA-
FITC-BSA NPs and quantified using the Bradford Protein 
Assay. The percentage of the encapsulation efficiency (EE%) 
was calculated according to the following equation:
 
EE% =  (amount of protein released from the NPs/
[amount of unbound BSA in the supernatant 
during the washing steps + amount of protein 
released from the NPs]) ×100  
(1)
Loading of BSA was calculated using the following 
formula:
 
Loading% =  (amount of protein/[amount of 
protein + amount of polymeric 
matrix]) ×100  
(2)
cell culture
THP-1 monocyte/macrophage cell line was obtained from the 
American Type Culture Collection43,44 and were maintained 
in RPMI 1640 supplemented with 10% heat-inactivated 
fetal bovine serum (FBS), 50 µg/mL gentamicin, and 2 mM 
l-glutamine at 37°C, 5% CO
2
. MDMs were obtained by 
adding PMA to the culture medium at a final concentration 
of 10 ng/mL. Cells were incubated for 4–6 days to allow the 
monocytes to differentiate into macrophages.
cellular uptake and internalization
In order to evaluate the cellular uptake and internalization 
of BSA-loaded PLGA NPs, we used FITC-labeled BSA to 
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prepare the NPs. For flow cytometry analysis, THP-1 cells 
were seeded in 24-well tissue culture plates at a density of 
2×105 cells per well and allowed to differentiate. After 4 days, 
MDMs were washed and fresh culture medium containing 
various concentrations of PLGA-FITC-BSA NPs was added 
to the wells. Cells were incubated for 3 hours and then washed 
with PBS. Cellular uptake of fluorescent PLGA-FITC-BSA 
NPs was analyzed by flow cytometry (FACSCalibur™; BD 
Biosciences, San Jose, CA, USA). To further confirm cel-
lular uptake of the PLGA-FITC-BSA NPs and study their 
internalization into MDMs, confocal microscopy analyses 
were performed. Cells were seeded in glass flat-bottomed 
96-well tissue culture plates for confocal microscopy (Mat-
Tek, Ashland, MA, USA) at a density of 2×104 cells per well 
with culture medium containing PMA to allow differentia-
tion. After 6 days of incubation, differentiated THP-1 cells 
were washed with PBS and fresh culture medium containing 
100 µg/mL of fluorescent PLGA-FITC- BSA NPs or free 
FITC-BSA in solution was added to the wells. In control 
wells, only culture medium was added to the cells. Cells were 
incubated at 37°C for 3 hours, then washed with PBS, and 
fresh culture medium without NPs was added to each well. 
Uptake and intracellular localization of PLGA-FITC-BSA 
NPs or free FITC-BSA in viable MDM cells was visualized 
using laser scanning confocal microscopy (LSM700; Carl 
Zeiss Canada, Toronto, ON, Canada).
cell-biocompatibility assay
THP-1 cells were seeded in flat-bottomed 96-well plates 
(Corning) at a density of 2×104 cells per well and allowed 
to differentiate. After 4 days, MDMs were washed with PBS 
and fresh culture medium containing various concentrations 
of either unloaded PLGA or PLGA-BSA NPs was added to 
the cells. After 48 hours of exposure to the NPs, cell viabil-
ity was determined by the CellTiter-Blue® Assay (Promega 
Corporation) based on the ability of living cells to convert a 
redox dye (resazurin) into a fluorescent end product (reso-
rufin) and quantified by the ratio to the control. Untreated 
cells served as 100% cell viability.
Neutrophil apoptosis assay
Blood donations were obtained from informed and consent-
ing individuals and the study protocol was approved by the 
INRS–Institut Armand-Frappier Research Centre Ethics 
Committee. Freshly isolated human PMNs from healthy 
donors were isolated by dextran sedimentation followed by 
centrifugation over Ficoll-Hypaque (Pharmacia Biotech Inc., 
Quebec, Canada) as previously described.45–47 Purity (.98%) 
was verified by cytology from cytocentrifuged preparations 
stained with Diff-Quick staining (Thermo Fisher Scientific). 
Cell viability was monitored by trypan blue exclusion before 
and after each treatment and was always $99%. PMNs were 
cultured in RPMI 1640-HEPES-P/S, supplemented with 10% 
heat-inactivated autologous serum, and 10×106 cells/mL 
were treated with or without increasing concentrations of NPs 
for 24 hours. Control cultures were incubated with buffer 
(untreated control), 65 ng/mL granulocyte-macrophage col-
ony-stimulating factor (GM-CSF, negative control), or plant 
lectin Viscum album agglutinin 1 (positive control). Apoptosis 
was assessed by cytology as described earlier.45,46 Cells were 
examined by light microscopy at 400× final magnification, and 
apoptotic neutrophils were defined as cells containing one or 
more characteristic, darkly stained pyknotic nuclei.
animal study
CD-1 female mice (6−8 weeks of age) from Charles River 
Laboratories (St-Constant, QC, Canada) after a period of 
acclimation of 1 week were anesthetized with isofurane at 
days 0 and 3 to create an air pouch by injecting 3 mL of ster-
ile air subcutaneously in the back (with a 26-gauge needle) 
as previously described.45,48–50 At day 6, 1 mL of water or 
various concentrations of NPs or free BSA was injected into 
the air pouch. After 6 hours, mice were sacrificed by CO
2
 
asphyxiation, the pouches were washed three times (once 
with 1 mL and then twice with 2 mL of Hank’s Balanced Salt 
Solution containing 10 mM EDTA), and the exudates were 
centrifuged. Cells were resuspended at a density of 0.5×106 
cells/mL, spread onto microscope slides, and stained with 
Hema-Stain for identification/quantification of leukocyte 
cell subpopulations. Experiments were performed as per 
protocols approved by Animal Use and Care Committees at 
INRS-Institut Armand-Frappier.
statistics
Statistical analysis was performed using Sigma Stat for 
Windows (version 3.0) for the Student’s t-test or SigmaPlot 
(version 11.0) for the ANOVA analysis. A P-value of ,0.05 
was considered as statistically significant. All data are pre-
sented as mean ± standard error of the mean (SEM) unless 
otherwise noted.
Results
Morphology and physicochemical 
properties of the nanoparticles
Using the double-emulsion solvent evaporation method, we 
were able to successfully prepare spherical NPs as shown in the 
electron microscope image (Figure 1A). Particle size analysis 
and zeta potential of BSA-loaded and unloaded PLGA NPs 
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were determined by DLS in different solvents and summarized 
in Table 1. The mean particle size of the PLGA-BSA NPs in 
water was 186±17 nm compared with 160±8 nm for unloaded 
PLGA NPs, indicating the presence of the protein. In cell 
culture medium supplemented with 10% serum, we observed 
a reduction in the size of the PLGA-BSA NPs to 126±2 nm, 
whereas the size of the unloaded control PLGA NPs increased 
to 195±18 nm. Surface charge was negative in all conditions, 
but a significant increase in zeta potential was observed 
when NPs were dispersed in saline buffer or cell culture 
medium as compared with water. As summarized in Table 1, 
PLGA-BSA NPs had a zeta potential of −12.3±2.5 mV in water 
compared with −30.8±3.2 for unloaded PLGA NPs. In saline 
or RPMI, zeta potential increased to reach up to −4.6 mV for 
PLGA-BSA and −2.3 mV for PLGA NPs. To note, addition 
of serum in RPMI did not affect the surface charge of the NPs. 
The polydispersity index was 0.041 and 0.195 for unloaded 
PLGA NPs (Figure 1B) and PLGA-BSA NPs (Figure 1C), 
? ????????? ?????????????????
??????? ???????????????????????????? ???????????????????
??
??
??
??
?
? ? ?? ????????????????
????
????
????
?
?????
??????????????????????????????????????
? ?????????????????????
?
??
??
??
?
?
?
? ? ?? ????????????????
????
????
????
?
?????
????????????????????????????????????
Figure 1 Morphology and size distribution of the Plga NPs.
Notes: (A) TeM image of Plga NPs and size distribution in water of (B) unloaded Plga NPs, and (C) Plga-Bsa NPs.
Abbreviations: Plga, poly(lactic-co-glycolic) acid; NPs, nanoparticles; TeM, transmission electron microscope; Bsa, bovine serum albumin; PDI, polydispersity index.
Table 1 Particle size and zeta potential in different solvents
PLGA PLGA-BSA
Diameter (nm) Zeta potential (mV) Diameter (nm) Zeta potential (mV)
Water 159.87±8.26 −30.78±3.24 185.66±17.12 −12.27±2.52
saline 180.63±5.23 −2.31±0.13 161.57±0.57 −4.59±0.26
rPMI 195.57±4.46 −2.38±0.13 175.07±1.33 −5.50±0.19
rPMI +10% FBs 195.00±17.90 −2.82±0.13 126.30±2.48 −5.61±0.17
Note: Data represent mean ± seM.
Abbreviations: Plga, poly(lactic-co-glycolic) acid; Bsa, bovine serum albumin; FBs, fetal bovine serum; seM, standard error of the mean; rPMI, roswell Park Memorial 
Institute.
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respectively. The DLS results indicated a narrow size distribu-
tion and a good colloidal stability of the NPs (Figure 1B and 
C). The results were reproducible in multiple batches. The size 
of FITC-BSA-loaded PLGA NPs was 207 nm, and the zeta 
potential of the NPs in water was −18 mV (data not shown).
ee% of the Bsa protein and stability of  
nanoparticles
EE% of BSA was evaluated at 38%±5% from four different 
experiments done in triplicates. BSA content in the NPs and 
free BSA in supernatants were determined by the Bradford 
method as described in the Materials and methods section. 
The percentage of loading of BSA in the NPs was 3.85%. 
EE% of FITC-BSA was evaluated at 27.6%±1.1% from 
triplicate measurements. To assess the stability of the NPs, 
fluorescein-labeled BSA-loaded PLGA NPs were prepared, 
stored at 4°C, and monitored for up to 1 month. THP-1 MDMs 
were treated with 100 µg/mL of PLGA-FITC-BSA NPs for 
3 hours, and then cell-associated fluorescence was analyzed 
by flow cytometry. As shown in Figure S1, fluorescence was 
detected up to the end of the experiment (28 days). Weaker 
fluorescence intensity was observed at days 21 and 28; 
however, the difference between cell-associated fluorescence 
from day 0 up to day 28 was not found to be statistically 
significant. These results indicate that the NPs are stable at 
least for 1 month.
cellular uptake and internalization
In order to evaluate cellular uptake, THP-1 MDM cells were 
treated with different concentrations of PLGA-FITC-BSA 
NPs for 3 hours, and fluorescence intensity of the resulting 
labeled cells was measured by flow cytometry. Results are 
shown in Figure 2. Flow cytometry data demonstrated that 
PLGA-FITC-BSA NPs are rapidly and efficiently taken 
up by THP-1 MDMs (Figure 2A). A significant dose-
dependent increase in fluorescence was observed from 
20 up to 200 µg/mL and then increased more slowly up to 
the highest concentration tested, 1,000 µg/mL (Figure 2B). 
We next compared the cellular uptake of PLGA-FITC-BSA 
with free FITC-BSA. THP-1 MDM cells were exposed to 
Figure 2 Cellular uptake of BSA encapsulated into PLGA NPs analyzed by flow cytometry.
Notes: THP-1 monocyte-derived macrophages were treated with different concentrations of PLGA-FITC-BSA NPs for 3 hours, and fluorescence intensity was measured 
by flow cytometry. (A) Histograms showing fluorescence intensity at different NPs concentrations of a representative experiment. (B) Mean ± SEM fluorescence intensity 
of at least two experiments.
Abbreviations: Plga, poly(lactic-co-glycolic) acid; NPs, nanoparticles; BSA, bovine serum albumin; FITC, fluorescein isothiocyanate; SEM, standard error of the mean; FU, 
fluorescence unit.
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different concentrations of free FITC-BSA or PLGA-FITC-
BSA for 3 hours, and then the fluorescence was measured by 
flow cytometry. Data are shown in Figure 3. In contrast to 
Figure 2 in which the concentration represented the amount 
of NPs, in this study, the data are expressed in terms of 
the amount of BSA. As shown in Figure 3, cell-associated 
fluorescence increased up to fivefold when the protein was 
incorporated into PLGA NPs compared with free delivery, 
demonstrating that uptake of BSA is more efficient when 
loaded into PLGA NPs.
Flow cytometry analysis cannot determine if the PLGA 
NPs are inside the cells or simply on the cell surface. There-
fore, to further investigate whether the NPs was indeed taken 
up and internalized within the cells, we performed confocal 
laser scanning microscopy studies. The data highlighted in 
Figure 4 are representative images of live cells incubated 
with PLGA-FITC-BSA NPs or free FITC-BSA for 3 hours. 
While in untreated control cultures (Figure 4A), no fluores-
cence was detected. In cells treated with PLGA-FITC-BSA 
NPs, fluorescence intensity increased with the concentration 
of NPs (Figure 4C–F). At the lowest dose tested, 20 µg/mL, 
a high level of cellular uptake was already observed 
(Figure 4C), and at 100 µg/mL, almost all cells have had 
taken up the BSA-loaded PLGA NPs (Figure 4D). These 
results support the flow cytometry data and demonstrate 
that the PLGA-FITC-BSA NPs were efficiently and rapidly 
taken up by the cells. In addition, the confocal analysis 
allowed us to visualize the intracellular distribution of 
the fluorescent BSA either free or encapsulated into the 
Figure 3 Flow cytometry analysis of cellular uptake.
Notes: Monocyte-derived macrophages were exposed to various concentrations of 
fluorescent BSA alone or PLGA-FITC-BSA NPs for 3 hours. Then cells were washed 
and analyzed by flow cytometry.
Abbreviations: Plga, poly(lactic-co-glycolic) acid; NPs, nanoparticles; Bsa, bovine 
serum albumin; FITC, fluorescein isothiocyanate; FU, fluorescence unit.
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Figure 4 Confocal microscopy analysis of internalization of fluorescent BSA in live monocyte-derived macrophage cells.
Notes: (A) Untreated control ThP-1 MDM cells. ThP-1 MDM cells were treated for 3 hours with (B) 1 µg/ml of FITc-Bsa alone (equivalent amount of Bsa found in 
64 µg/ml of Plga-FITc-Bsa NPs), (C) 20 µg/ml, (D) 100 µg/ml, (E) 500 µg/ml, and (F) 1,000 µg/ml of Plga-FITc-Bsa NPs. Images are representative of three separate 
experiments. Magnification 630×. Green fluorescence: FITC-BSA.
Abbreviations: Bsa, bovine serum albumin; MDM, monocyte-derived macrophages; Plga, poly(lactic-co-glycolic) acid; NPs, nanoparticles; FITC, fluorescein isothiocyanate.
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PLGA-FITC-BSA NPs. Z-stack analysis (data not shown) 
and Figure 4C–F show that the fluorescence is distributed 
inside the cells, confirming the internalization of the NPs. By 
comparing the cellular uptake of free FITC-BSA (Figure 4B) 
with the uptake of PLGA-FITC-BSA (Figure 4C–F), we 
again observed a higher rate of delivery when FITC-BSA was 
incorporated into PLGA NPs, confirming the flow cytometry 
data (Figure 3).
safety evaluation
cytotoxicity
Next, we ran a series of experiments to define the safety and 
inflammatory properties of the NPs. First, we evaluated the 
effects on THP-1 MDMs on enzymatic activity after 48 hours 
of exposure to increased concentrations of unloaded PLGA 
or PLGA-BSA NPs using the CellTiter-Blue® colorimetric 
cell viability assay. As illustrated in Figure 5, PLGA NPs 
(Figure 5A) did not affect cell viability of MDMs up to the 
maximum concentration tested, 500 µg/mL. Interestingly, 
when the cells were treated with low doses (5 or 50 µg/mL) 
of PLGA-BSA NPs, we observed an increase in the number 
of cells (Figure 5B). This increase was not observed with 
unloaded PLGA NPs (Figure 5A). At higher concentrations of 
PLGA-BSA NPs, cell viability was not affected (Figure 5B). 
PLGA NPs were also evaluated for their cytotoxicity on the 
TZM-bl epithelial cell line model, and again, no effect on cell 
viability was observed up to the highest concentration used 
in these cells, 4,000 µg/mL (data not shown).
Inflammatory properties
The inflammatory profile of the PLGA NPs was performed 
with a neutrophil apoptosis assays. As illustrated in Figure 6, 
neither PLGA nor PLGA-BSA NPs affected apoptosis of 
human neutrophils up to the highest concentration tested 
(1,000 µg/mL). As expected, V. album agglutinin increased 
and GM-CSF inhibited neutrophil apoptosis when compared 
with the controls.51,52 To further investigate the pro-inflam-
matory property of the PLGA NPs, we also conducted in 
vivo assays using the murine air pouch model. This model 
has been commonly used to determine pro-inflammatory 
effects of molecules including the evaluation of acute pro-
inflammatory activity of NPs.53–55 As illustrated in Figure 7, 
administration of 10, 100, 250, 500, or 1,000 µg/mL of 
unloaded PLGA NPs or 10, 100, 250, 500 µg/mL of PLGA-
BSA NPs did not significantly increase the total number of 
attracted leukocytes into the air pouch 6 hours postinjection 
when compared with the control mice. However, adminis-
tration of 1,000 µg/mL of PLGA-BSA NPs significantly 
increased leukocyte infiltration into the air pouch to the 
same extent of theTiO
2
 positive control NPs (Figure 7B). 
However, when BSA alone was administered into the air 
pouch at concentrations equivalent to the amount of BSA 
found in 1,000, 2,000, or 4,000 µg/mL of PLGA-BSA NPs, 
we did not observe increased leukocyte infiltration into the 
air pouch (Figure 7C). Cytology examinations revealed 
that 75% of the leukocytes attracted into the air pouch by 
1,000 µg/mL of PLGA-BSA NPs were neutrophils compared 
with 56% in control mice or 93% when TiO
2 
NPs were 
injected (Figure 8B). The remainders of the leukocytes were 
mononuclear cells. Although the total number of leukocytes 
attracted into the air pouch did not increase when unloaded 
PLGA NPs were administered, the proportion of PMNs was 
slightly higher (72%) compared with the control mice (63%), 
but this difference was not found statistically significant 
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Figure 5 effects of NPs on cell viability of ThP-1 MDMs.
Notes: cells were treated with different concentrations of (A) Plga and (B) Plga-Bsa NPs for 48 hours, then washed, and cell viability was determined by the 
colorimetric cellTiter-Blue® assay. Percentage of cell viability was calculated relative to untreated control cells. Values represent mean ± seM from at least two experiments 
(n=4 for Plga; n=8 for Plga-Bsa).
Abbreviations: NPs, nanoparticles; MDMs, monocyte-derived macrophages; Plga, poly(lactic-co-glycolic) acid; Bsa, bovine serum albumin; seM, standard error of the 
mean.
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Figure 6 effects of NPs on neutrophil apoptosis.
Notes: PMNs (10×106 cells/ml) were incubated with buffer (control), 65 ng/ml gM-csF, Vaa-1, or the indicated concentrations of (A) Plga NPs, or (B) Plga-Bsa NPs, 
and apoptosis was assessed by cytology. results are mean ± seM (n=3). *Indicates P,0.05 versus the control and ***indicates P,0.001 versus the control.
Abbreviations: NPs, nanoparticles; PMNs, polymorphonuclear neutrophils; gM-csF, granulocyte-macrophage colony-stimulating factor; Vaa-1, Viscum album agglutinin 1; 
seM, standard error of the mean; Plga, poly(lactic-co-glycolic) acid.
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Figure 7 Induction of leukocyte infiltration by PLGA NPs in vivo.
Notes: Murine air pouches were raised in cD-1 mice before the injection of water (control) or the indicated concentrations of (A) Plga NPs, (B) Plga-Bsa NPs, and 
(C) Bsa protein alone. exudates were harvested after 6 hours, and the total number of leukocytes was calculated. results are the mean ± seM (n$4). *P,0.05 versus the 
control, **P,0.01 versus the control.
Abbreviations: Plga, poly(lactic-co-glycolic) acid; NPs, nanoparticles; Bsa, bovine serum albumin; seM, standard error of the mean.
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Figure 8 analysis of leukocyte subsets attracted in the air pouches.
Notes: Murine air pouches were raised in cD-1 mice before the injection of water (control) or the indicated concentrations of (A) Plga NPs, (B) Plga-Bsa NPs, or 
(C) BSA protein alone. Exudates were harvested after 6 hours and the cell populations were identified by cytology. Results are the means ± seM (n$4). *P,0.05 versus the 
control, **P,0.01 versus the control, ***P,0.001 versus the control by aNOVa. Numbers in parentheses are the number of cells ×106.
Abbreviations: Plga, poly(lactic-co-glycolic) acid; NPs, nanoparticles; Bsa, bovine serum albumin; seM, standard error of the mean; PMNs, polymorphonuclear 
neutrophils.
????????????
????????
??
??
??
??
???
? ?
?
??
??
??
??
???
??????
???????? ?? ??
????????????
?????????
?????
?????
????
?
???
?????
?????
????
?
???????????? ????????????
??????
??????
??????
??????
??????
?????? ??????
??????
??????
??????????????????
??????
????????????
??????
??????
??????
??????
?? ? ?? ??? ??? ?? ? ?????? ?????
????????????????
??????? ?? ??? ??? ?????
?
?
??
??
??
??
??? ???
??????
??????
??????
???????
???????????? ??????
?????? ????????????
???
?????
?????
????
?
??????? ?? ? ?? ?? ?????????????
????????? ??????????????????????
(Figure 8A). Finally, BSA alone at any of the concentrations 
evaluated showed the same proportion of cell subpopulations 
as in the control mice (Figure 8C).
Discussion
Like CD4+ T cells, monocyte/macrophage lineage cells are 
regarded as the early targets for HIV-1 infection. Because 
macrophages are widely distributed and present in many 
tissues of the body, they not only play important roles in 
disease control and progression but can also contribute to 
virus dissemination throughout the body including in the 
central nervous system. Therefore, HIV-1-infected mac-
rophages might play a pivotal role in virus transmission, 
the establishment of latent reservoirs, and AIDS patho-
genesis. As such, eliminating or preventing viral infection 
in macrophages is a key element to achieve viral eradica-
tion. Previous studies have demonstrated the potential of 
PLGA-based NPs to deliver drugs in vitro and in vivo, but 
the toxicity profile of PLGA NPs have not yet been fully 
investigated. Therefore, the objective of the present study 
was to further characterize PLGA-based NPs for the delivery 
of therapeutic proteins into human macrophages with an 
emphasis on a better characterization of their inflammatory 
profile, which is currently poorly documented. We have 
prepared PLGA NPs containing BSA that remain stable in 
cell culture medium supplemented with 10% serum with a 
homogenous size of 126 nm and a negative surface charge 
(zeta potential =−5.61 mV). In addition, these PLGA-BSA 
NPs were found to be stable at 4°C up to at least 1 month in 
solution. Specifically, the size of PLGA NP increases from 
156 to 167 nm, and zeta potential decreases from −33.3 to 
−31.5 mV, respectively, after storage for 2 months in water 
(data not shown). However, further experiments are required 
in order to confirm their stability for future use in clinical 
application. Indeed, the change in fluorescence observed 
could be assumed to be dependent from loss of albumin sta-
bilization or change in surface characteristics of NPs, which 
have not been investigated in this study. Most importantly, 
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these PLGA NPs did not agglomerate in serum-containing 
culture medium and remained well below 200 nm in diameter. 
This was crucial for the present study because we wanted to 
evaluate the NPs in vitro and in vivo, so their properties in 
biological media had to be characterized.
Macrophages obtained by differentiation of THP-1 
monocytes were chosen as the in vitro cell model because 
these have been shown to be a relevant in vitro human 
macrophage models43,44 and have been used successfully to 
investigate the toxicity of NPs.56–58 The use of FITC-labeled 
BSA allowed us to detect and localize the protein either 
free or encapsulated into PLGA NPs and monitor its uptake 
and delivery process in THP-1 MDM cells. Flow cytometry 
analysis demonstrated that BSA-loaded PLGA NPs are easily 
taken up by human MDMs and that BSA delivery in this cell 
model is increased fivefold when the protein is encapsulated 
into PLGA NPs. Our results are in agreement with a previ-
ous study showing a similar increase range of cell uptake of 
PLGA-formulated antituberculosis drugs in human MDMs.40 
The authors observed a three- and tenfold increase in human 
MDMs delivery of a hydrophobic isoniazid derivative and 
rifampicin, respectively, when compared with free drugs. 
Using live-cell confocal microscopy, we further demon-
strated that PLGA-FITC-BSA NPs are rapidly taken up and 
that higher uptake of BSA is achieved when delivered by 
PLGA nanocarriers compared with its free form in solution. 
We also confirmed their internalization in human MDMs as 
they were found inside the cells within 3 hours. This study 
demonstrates and supports previous studies showing the rapid 
uptake of PLGA NPs by macrophages. The focus of this 
study was not to investigate the uptake mechanism in human 
MDMs, but it has been previously demonstrated that PLGA 
NPs are phagocytosed by macrophages within 30 minutes, 
and electron microscopy studies have shown that they are 
found within the cytoplasm of human MDMs 45 minutes 
following treatment. Therefore, as shown in this study and 
previous studies, the use of polymeric-based nanocarri-
ers is a promising strategy to deliver therapeutic agents in 
human MDMs and to target pathogens that proliferate inside 
macrophages including visceral leishmaniasis, malaria, and 
tuberculosis.29,38–40
It is well known that PLGA-based material is suitable 
for therapeutic application since it is biodegradable and 
show low toxic effects. The results of our cytotoxicity 
assays support previous studies showing that PLGA NPs do 
not significantly affect human MDM cell viability.38,39,56–58 
In the present study, PLGA NPs were not found to be 
cytotoxic for neither TZM-bl nor human MDMs when cells 
were exposed for 48 hours at concentrations up to 4,000 or 
500 µg/mL, respectively. In 2013, Shibata et al reported 
no significant cytotoxicity up to 28 days of treatment with 
500 µg/mL of PLGA NPs using three cell models including 
the human monocyte U937 cell model.39 Therefore, we and 
others have demonstrated that PLGA NPs do not affect cell 
activity even at concentrations well above therapeutically 
relevant doses (100 µg/mL and below), confirming their 
potential as delivery nanocarriers for therapeutic applications. 
Interestingly, in this study, we observed that cells treated 
with PLGA-BSA NPs showed an increase in cell prolifera-
tion. We also observed an increase when cells were treated 
with BSA alone at equivalent amount found in the PLGA 
NPs but to a lesser extent than the PLGA-BSA NPs (data 
not shown). This might be explained in part by the fact that 
cells were exposed to higher concentrations of BSA when 
it was delivered by PLGA NPs compared with free BSA in 
solution, confirming again higher delivery of BSA when 
the protein is encapsulated. More experiments are needed 
though to confirm this.
One of the major toxic effects of NPs frequently reported 
in the literature is inflammation.57,59–61 Because PMNs are 
key players in innate immunity and inflammation,62,63 it is 
important to evaluate the effects of NPs on the response and 
functions of human neutrophils. Therefore, in this study, 
we wanted to further investigate the toxicological profile of 
PLGA NPs by evaluating their effects on human PMNs. To 
do so, we performed in vitro apoptosis neutrophil assays. 
The resolution of inflammation is known to occur by the 
elimination of apoptotic PMNs, so the modulation of neu-
trophil apoptosis may indicate pro-inflammatory (inhibition 
of apoptosis) or anti-inflammatory (induction of apoptosis) 
properties depending on whether the agent inhibits or induces 
apoptosis, respectively. To determine whether PLGA NPs 
had pro- or anti-inflammatory effects, we investigated their 
ability to modulate human primary PMNs apoptosis in vitro. 
To validate the assay, control cultures were exposed to either 
the cell growth factor GM-CSF known to act as an inhibi-
tor of apoptosis or to the plant lectin V. album agglutinin 1, 
a potent pro-apoptotic molecule that we used in this study 
as an inducer of neutrophil apoptosis. In contrast to other 
types of NPs such as ZnO or TiO
2
 that have been found 
to modulate PMN apoptosis,47,64 in this study, PLGA NPs 
were not found to have inflammatory activities. The NPs did 
not significantly inhibit or induce PMN apoptosis in vitro. 
Of note, this is the first study to report the lack of inflam-
matory effect of PLGA NPs using the neutrophil apoptosis 
assay. Based on these results, one can speculate that these 
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PLGA NPs would not disturb normal homeostasis in vivo 
by modifying the life span of PMNs. Hence, they should 
not induce accumulation of PMNs in tissues by inhibiting 
apoptosis and thus induce inflammation in vivo. To confirm 
this and further investigate the inflammatory properties of 
the PLGA NPs, we used the murine air pouch model to 
determine whether our PLGA NPs caused leukocyte infil-
tration in vivo as in our previous studies with TiO
2
 NPs.54 
We and others have previously used this in vivo model to 
classify the degree of pro-inflammatory potential of NPs, 
but it is the first time that the inflammatory effects of PLGA 
NPs are evaluated using this animal model. In this study, we 
did not observe an increase in leukocyte infiltration into the 
air pouch when PLGA NPs were injected up to the highest 
concentration tested (1,000 µg/mL) demonstrating their 
lack of inflammatory effect. Furthermore, when PLGA NPs 
were loaded with BSA, a significant increase in the number 
of leukocytes recruited into the air pouch was noted when 
compared with equivalent amount of BSA in solution, sug-
gesting that encapsulation of BSA into the PLGA NPs might 
have protected it from degradation for a longer period of 
time allowing leukocyte recruitment. More experiments are 
needed to confirm that this was the case. Nevertheless, these 
results show the potential of PLGA nanocarrier to transport 
and deliver a protein in vivo and confirm its low toxicity 
profile. Finally, in agreement with the low pro-inflammatory 
properties of the PLGA NPs observed in the neutrophil 
apoptosis assay and in the air pouch murine model, we found 
that they did not significantly increase cytokine secretion of 
interleukin (IL)-1β, IL-6, IL-10, and TNF-α in differentiated 
THP-1 cells up to the highest concentration tested (400 µg/
mL) 48 hour post-treatment as determined by a luminex 
multiplex assay (Table S1). Further evaluation of the effect 
of these PLGA NPs on the activation of the inflammasome 
is necessary to confirm these preliminary observations.
Conclusion
PLGA NPs loaded with BSA protein were successfully 
synthesized and rapidly internalized in macrophages. 
Encapsulation in PLGA NPs significantly increased cellular 
uptake of the BSA protein in macrophages compared with 
the free protein in solution. In addition, the PLGA NPs did 
not cause cytotoxicity and showed low inflammatory prop-
erties. Indeed, they did not modulate apoptosis in vitro in 
the neutrophil apoptosis assay and did not induce leukocyte 
infiltration in vivo in the murine air pouch model. Altogether, 
the results of this study further demonstrate the safety and 
efficiency of PLGA NPs to deliver therapeutic molecules in 
human MDMs. Further study is necessary to determine if 
these NPs could be a promising strategy for the prevention 
and eradication of HIV-1 infection.
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Supplementary materials
Figure S1 stability of the nanosuspensions.
Notes: ThP-1 monocyte-derived macrophages were treated for 3 hours with 100 µg/ml of Plga-FITc-Bsa NPs stored at 4°c for the indicated period of time and 
fluorescence was analyzed by flow cytometry. Values represent mean fluorescence intensity ± seM from at least two experiments (n=4–6). Differences between groups were 
not found statistically significant at P=0.05.
Abbreviations: Plga, poly(lactic-co-glycolic) acid; FITC, fluorescein isothiocyanate; BSA, bovine serum albumin; NPs, nanoparticles; SEM, standard error of the mean; FU, 
fluorescence unit.
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Table S1 effects of Plga nanoparticles on cytokine secretion
PLGA
(µg/mL)
IL-1β
(pg/mL)
IL-6
(pg/mL)
IL-10
(pg/mL)
TNF-α
(pg/mL)
0 9.57 ,0.20 ,0.5 ,0.40
2 7.88 ,0.20 0.79 0.72
200 7.31 ,0.20 1.07 ,0.40
400 21.77 0.33 1.36 1.7
Notes: ThP-1 monocyte-derived macrophages were exposed to Plga nanoparticles for 48 hours and cytokine secretion was measured in supernatants by the luminex 
multiplex bead assay. Data represent value of pooled triplicates from one experiment.
Abbreviations: Plga, poly(lactic-co-glycolic) acid; Il, Interleukin; TNF, tumor necrosis factor.
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